685
views
0
recommends
+1 Recommend
1 collections
    1
    shares

      2023 Journal Citation Reports Journal Impact Factor is 0.9. Scopus Citescore 0.8. 

      Interested in becoming a CVIA published author?

      • Platinum Open Access with no APCs. 
      • Fast peer review/Fast publication online after article acceptance.

      Submissions should be made electronically at: https://mc04.manuscriptcentral.com/cvia-journal.

      Please refer to the Author Guidelines at https://cvia-journal.org/instructions-to-authors/ before submission.

       

      scite_
       
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hypertrophic “Obstructive” Cardiomyopathy: Role of Systolic Anterior Motion of the Mitral Valve

      Published
      research-article
      , MD, MACC 1 ,
      Cardiovascular Innovations and Applications
      Compuscript
      Bookmark

            Main article text

            If systolic anterior motion (SAM) of a redundant anterior leaflet of the mitral valve is combined with systolic thickening of an asymmetric septum, (ASH), a narrow outflow channel of the left ventricle is formed. This narrowed outflow channel is then responsible for the mid systolic pressure difference between the body of the left ventricle and the out flow area of the left ventricle. This results in hypertrophic “obstructive” cardiomyopathy (HOCM).

            Many years ago, my friend, Dr. William Spencer, then at Baylor College of Medicine, was one of the first cardiologists in the USA to perform Alcohol septal ablation in symptomatic hypertrophic cardiomyopathy patients with systolic pressure differences in the left ventricular outflow area.

            Dr. Spencer told me that patients who undergo alcohol septal ablation, almost immediately experience a marked decrease of symptoms. This made me wonder why patients with hypertrophic cardiomyopathy and an outflow area pressure difference get symptom relief immediately after alcohol septal ablation?

            It seems to me, that since most of these patients have some mitral insufficiency which easily produces symptoms, the only thing that I can think of that would decrease mitral incompetence acutely would be the combination of poor septal thickening and normalizing closure of the mitral valve by decreasing the amount of systolic anterior motion (SAM) of the mitral valve.

            My rationale is that a regional infarction of the septum may result in failure of the ventricular septum to thicken during systole. This in turn may result in widening of the narrowed left ventricular outflow area during systole. When that area is widened, I can envision the Venturi effect decreasing, which then may decrease the systolic anterior motion of the redundant anterior leaflet of the mitral valve. This prevents the anterior leaflet of the mitral valve from hitting the septum during mid systole, preventing or decreasing the pressure difference in the left ventricular outflow area. The anterior leaflet of the mitral valve may then co-apt properly or near properly with the posterior leaflet. As a result, the amount of mitral insufficiency is decreased, decreasing left atrial pressure, pulmonary venous pressure and pulmonary capillary pressure, and thus reducing symptoms.

            Septal myectomy at the time of surgery probably does the same thing, but it takes somewhat longer for the patient to recover since they have had open chest surgery. The surgical procedure (Morrow procedure) focuses on the widening of the left ventricular outflow area due to septal reduction surgery. In contrast, those who undergo alcohol septal ablation of the hypertrophied asymmetric septum (regional myocardial infarction) get a similar reduction of the hypertrophied septum, (at least there is less systolic thickening of the asymmetric septum), but they obtain immediate relief, since they do not have to recover from open chest surgery.

            Sorajja et al. [1] recently published an article in which percutaneous plication of the mitral valve (mitral clip) was used to “reduce left ventricular outflow area pressure differences across the outflow area”. The authors focus is on the systolic anterior motion the mitral valve. As I understand it, the anterior mitral leaflet is restrained by the mitral clip, from protruding into the left ventricular area and creating left ventricular outflow area pressure differences. Septal reduction is not involved in this therapy.

            Six patients with drug refractory heart failure symptoms underwent this procedure. Five of these patients had a successful result. They found that following mitral clip implantation there was immediate relief of pressure differences in the outflow area and decrease in mitral regurgitation in association with the fall in left atrial pressure and rise in cardiac output.

            Nothing is mentioned in this article about the time of symptom reduction, but importantly, long term benefits are recorded several years after the procedure. At follow-up, echocardiography demonstrated continued absence of systolic anterior motion of the anterior leaf of the mitral valve and significant reduction in mitral regurgitation.

            The authors make the point that this procedure directly targets the mitral valve and retards the mechanism of left ventricular outflow area pressure differences (SAM). In addition, using the mitral clip does not require an iatrogenic septal infarction or ventricular remodeling.

            Reference

            1. SorajjaP, PedersenWA, BaeR, LesserJR, JayD, LinD, et al. First experience with percutaneous mitral valve plication as primary therapy for symptomatic obstructive hypertrophic cardiomyopathy. JACC 20161; 67:28118.

            Author and article information

            Journal
            CVIA
            Cardiovascular Innovations and Applications
            CVIA
            Compuscript (Ireland )
            2009-8782
            2009-8618
            February 2017
            June 2017
            : 2
            : 2
            : 287-288
            Affiliations
            [1] 1Department of Medicine, University of Florida, Gainesville, FL 32610, USA
            Author notes
            Correspondence: C. Richard Conti, MD, MACC, Department of Medicine, University of Florida, Gainesville, FL 32610, USA, E-mail: richard.conti@ 123456medicine.ufl.edu
            Article
            cvia20160037
            10.15212/CVIA.2016.0037
            77733851-53c9-4f09-b4a2-093e589599ac
            Copyright © 2017 Cardiovascular Innovations and Applications

            This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc/4.0/.

            History
            Categories
            Commentary

            General medicine,Medicine,Geriatric medicine,Transplantation,Cardiovascular Medicine,Anesthesiology & Pain management

            Comments

            Comment on this article